FDA accepts NDA for BridgeBio’s encaleret for ADH1

BridgeBio Pharma announced FDA acceptance of a new drug application for encaleret targeting autosomal dominant hypocalcemia type 1, setting a target action date of May 8, 2027, and representing a potential blockbuster opportunity for the company.